GR3015850T3 - Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process. - Google Patents

Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process.

Info

Publication number
GR3015850T3
GR3015850T3 GR950400980T GR950400980T GR3015850T3 GR 3015850 T3 GR3015850 T3 GR 3015850T3 GR 950400980 T GR950400980 T GR 950400980T GR 950400980 T GR950400980 T GR 950400980T GR 3015850 T3 GR3015850 T3 GR 3015850T3
Authority
GR
Greece
Prior art keywords
chemotherapeutic agents
analogs
radiation
potentiators
compounds
Prior art date
Application number
GR950400980T
Other languages
English (en)
Inventor
Mark James Suto
William Richard Turner
Leslie Morton Werbel
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of GR3015850T3 publication Critical patent/GR3015850T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GR950400980T 1988-08-19 1995-04-17 Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process. GR3015850T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23470488A 1988-08-19 1988-08-19
US37275189A 1989-07-03 1989-07-03

Publications (1)

Publication Number Publication Date
GR3015850T3 true GR3015850T3 (en) 1995-07-31

Family

ID=26928219

Family Applications (1)

Application Number Title Priority Date Filing Date
GR950400980T GR3015850T3 (en) 1988-08-19 1995-04-17 Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process.

Country Status (7)

Country Link
EP (1) EP0355750B1 (el)
JP (1) JP2786896B2 (el)
AT (1) ATE117553T1 (el)
CA (1) CA1334969C (el)
DE (1) DE68920798T2 (el)
ES (1) ES2067508T3 (el)
GR (1) GR3015850T3 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2123402A1 (en) * 1991-11-12 1993-05-27 Jotham W. Coe Triazine derivatives for enhancing antitumor activity
US5391554A (en) * 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
US5587384A (en) * 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6380193B1 (en) 1998-05-15 2002-04-30 Guilford Pharmaceuticals Inc. Fused tricyclic compounds, methods and compositions for inhibiting PARP activity
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
EA006300B1 (ru) * 2000-10-30 2005-10-27 Кудос Фармасеутикалс Лимитед Производные фталазинона
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
DE60218458T2 (de) * 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
JP4500161B2 (ja) * 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
WO2004009556A1 (ja) * 2002-07-24 2004-01-29 Kyorin Pharmaceutical Co., Ltd. ４−置換アリール−５−ヒドロキシイソキノリノン誘導体
ES2380917T3 (es) 2002-10-01 2012-05-21 Mitsubishi Tanabe Pharma Corporation Compuestos de isoquinolina y su uso medicinal
EP1566380B1 (en) 2002-11-22 2012-01-11 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
SI1651658T2 (sl) 2003-08-01 2020-12-31 Mitsubishi Tanabe Pharma Corporation Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
DE102004028973A1 (de) * 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
UA105480C2 (uk) 2007-09-10 2014-05-26 Янссен Фармацевтика Н.В. Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
CN101821242B (zh) 2007-10-17 2013-07-24 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
ES2416459T3 (es) 2009-07-10 2013-08-01 Janssen Pharmaceutica, N.V. Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
DK2488515T3 (en) 2009-10-14 2017-02-27 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
PT2697218T (pt) 2011-04-13 2016-07-13 Janssen Pharmaceutica Nv Processo para preparação de compostos úteis como inibidores da sglt2
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB721286A (en) * 1951-02-16 1955-01-05 Smith Kline & French Internat Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives
FR2028672A6 (el) * 1968-03-06 1970-10-16 Rhone Poulenc Sa
US3674791A (en) * 1968-03-26 1972-07-04 Marion Laboratories Inc Benzamido 2 lower alkyl decahydroisoquinolines
DE2143745A1 (de) * 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
YU34792B (en) * 1972-07-18 1980-03-15 Pliva Pharm & Chem Works Process for preparing phthalazone
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona

Also Published As

Publication number Publication date
DE68920798T2 (de) 1995-05-18
JPH02124874A (ja) 1990-05-14
CA1334969C (en) 1995-03-28
EP0355750B1 (en) 1995-01-25
DE68920798D1 (de) 1995-03-09
ES2067508T3 (es) 1995-04-01
EP0355750A1 (en) 1990-02-28
ATE117553T1 (de) 1995-02-15
JP2786896B2 (ja) 1998-08-13

Similar Documents

Publication Publication Date Title
GR3015850T3 (en) Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process.
PT89111A (pt) Processo de preparacao de analogos de camptotecina hidrossoluveis, dos seus intermediarios e de composicoes que os contem
PH21554A (en) N-(4-piperidinyl)bicyclic condensed-2-imidazolamine derivatives
HUT43843A (en) Process for production of derivatives of benzimidasole and medical compounds containing thereof
HU206701B (en) Process for producing substituted flavonoid derivatives and salts and pharmaceutical compositions containing these compounds
CS404781A2 (en) Zpusob vyroby kyselin 3 (4 (2 hydroxy 3 isopropylaminopropoxy)fenyl)alkanovych
IL84917A0 (en) Quinolinone derivative,its preparation and pharmaceutical compositions containing it
EG20726A (en) Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors
IL86080A (en) Substituted alkoxy-2-alkyl-indan and 1,2,3,4-tetrahydro-naphthol,process for the preparation thereof and pharmaceutical compositions comprising the same
GB8401093D0 (en) Cephem compounds
DK183789A (da) 2-alkyl-3-benzoylbenzofuraner og laegemidler indeholdende disse
IE852823L (en) Medicaments containing spergualin
NZ213222A (en) 2-(3,5-dialkyl-4-hydroxyphenyl)-indole derivatives and pharmaceutical compositions
NZ222640A (en) Quinolinol derivatives and pharmaceutical compositions
IL81337A (en) Heptanoyl-glu-asp-ala-amino acid immunostimulants,process for their preparation and pharmaceutical compositions containing them
DE3362260D1 (en) (-)-15-deoxyspergualin, a process for the preparation of the same, and a pharmaceutical composition containing the same
EP0399626A3 (en) Substituted tetrahydroisoquinoline compounds, their production, and pharmaceutical compositions containing them
HU896174D0 (en) Process for the preparation of heterocyclic derivatives fusionated 1,2,3,4-tetrahydro-acridine and pharmaceutical compositions thereof
ES479005A1 (es) Un procedimiento para obtener derivados de quinazolina.
GR3002699T3 (en) Process for stabilising procaterol
EP0154491A3 (en) Quinate salts of the antimalarial compound mefloquine